The backtest results show that ABVX experienced poor short-term performance following earnings beats, with 0% win rates at 3 and 10 days and negative returns of -12.07% and -21.09%, respectively. However, the 30-day win rate improves to 50%, and the 30-day return is nearly flat at -1.23%, indicating some recovery over a longer horizon. This suggests that while immediate reactions to earnings beats were negative, the stock may stabilize or recover over time. Investors should be cautious about short-term trades on ABVX post-earnings beat but consider longer-term positions.

backtest_data

The backtest results for ABVX show a consistent 50% win rate across 3-day, 10-day, and 30-day periods following earnings misses, with returns improving over time, reaching 22.72% at 30 days. This indicates a mixed but potentially positive price reaction despite earnings underperformance. The maximum return of 74.04% occurring on day 33 suggests significant upside potential beyond the initial month. Investors might consider that ABVX can still offer attractive gains post-earnings miss, highlighting opportunities for strategic entry and holding beyond short-term volatility.

The backtest results show that the Biotechnology Industry experienced a slight negative impact following earnings beats, with a maximum return of only 0.29% occurring 15 days after the event. This suggests that despite positive earnings surprises, the sector does not significantly benefit in the medium term. The minimal positive return indicates limited upside potential from earnings beats in this industry.

This outcome implies that investors should be cautious about expecting strong gains solely based on earnings beats in the Biotechnology sector. Instead, a more comprehensive analysis of other factors may be necessary for investment decisions.

The backtest results show that earnings misses in the Biotechnology Industry have no significant impact, with a negligible maximum return of -0.08% observed three days after the event. This indicates that the industry’s stock prices do not react strongly or consistently to earnings misses over the tested period.

The lack of meaningful price movement suggests that other factors may dominate investor sentiment in this sector, reducing the relevance of earnings misses as a trading signal.

Investors might consider deprioritizing earnings miss events when making decisions related to Biotechnology stocks.

Backtest ABVX Earning Beats Expectations

Find all upcoming company earnings reports scheduled for jun 01 2026. Get details on which companies are reporting and their expected results.

Calendar